Report Details:
15 Companies Covered
200 Pages
Increasing Prevalence of Autoimmune Diseases will positively impact the Global Autoimmune Disease Diagnostics Market at a CAGR of 6.72% during the forecast period 2025 to 2035
Market Research Future (MRFR) has published a cooked research report on the “Global Autoimmune Disease Diagnostics Market” that contains information from 2025 to 2035. The Autoimmune Disease Diagnostics Market is estimated to register a CAGR of 7.01% during the forecast period of 2025 to 2035.
MRFR recognizes the following companies as the key players in the Global Autoimmune Disease Diagnostics Market: Novartis, Regeneron Pharmaceuticals, Pfizer, Gilead Sciences, Celgene, Merck & Co., Amgen, AstraZeneca, Eli Lilly, Teva Pharmaceuticals, Sanofi, Johnson & Johnson, Roche, Bristol-Myers Squibb, and AbbVie.
Market Highlights
The Global Autoimmune Disease Diagnostics Market is accounted for to register a CAGR of 7.01% during the forecast period and is estimated to reach USD 38.42 billion by 2035.
The world market is getting bigger because more people are getting autoimmune diseases like lupus, rheumatoid arthritis, and multiple sclerosis. Early detection has gotten faster thanks to awareness campaigns, the use of advanced diagnostic tools, and a growing interest in personalized medicine. The need for accurate and cheap diagnostics around the world keeps going up as more money is put into healthcare infrastructure and research. Tests are more accurate now that very advanced molecular assays and imaging methods are available. Companies are spending a lot of money on research and development to find biomarkers, make AI-based diagnostics, and come up with point-of-care testing solutions. Working with research centers and biotech companies is also helping to come up with new ideas. Governments in North America, Europe, and the Asia Pacific are making changes to screening programs to make them easier to access. Changes toward personalized therapy and remote disease monitoring are also good for the market's long-term growth. The industry will move forward during the forecast period because there are more patients, and diagnostic labs are growing quickly.
Segment Analysis
The Global Autoimmune Disease Diagnostics Market has been segmented based on Therapy Type, Disease Type, Route of Administration, End-user, and Regional.
Based on Therapy Type, the market has been segmented into Biologics, Corticosteroids, Immunosuppressants, Small Molecule Drugs. Among these, the Biologics segment is projected to dominate the market revenue through the projected period. Biologics are important because they work well for treating severe autoimmune diseases and have a specific effect, which is why they are a top choice for doctors.
Based on Disease Type, the market has been segmented into Rheumatoid Arthritis, Multiple Sclerosis, Lupus, Psoriasis, and Inflammatory Bowel Disease. Rheumatoid arthritis is a big part of this group because it is so common, which means that new treatments are always needed.
Based on End-user, the market has been segmented into Hospitals, Clinics, Homecare Settings. Hospitals make up a big part of this market because they have advanced infrastructure and specialized medical staff that can treat autoimmune diseases in a complete way.
Based on Route of Administration, the market has been segmented into Oral, Injectable, Topical. Injectable therapies are still the most popular because they often work quickly, which is important for many patients who want relief right away.
Region Analysis
By Region, the Autoimmune Disease Diagnostics Market is segmented into North America, Europe, Asia Pacific, South America, and the Middle East and Africa.
North America held the largest market share in 2024, owing to rising autoimmune disease cases, rapid adoption of modern diagnostic technologies, and strong reimbursement support and is projected to grow largely due to advanced healthcare infrastructure and high prevalence of autoimmune disorders. Europe follows with advancements in clinical research and early screening initiatives.
Asia Pacific is expected to witness significant growth due to rising healthcare spending, large patient demographics, and improvement in diagnostic infrastructure. Increasing awareness in emerging countries in South America and the Middle East, and Africa will further boost market performance over the forecast period.
Key Findings of the Study
• The Global Autoimmune Disease Diagnostics Market is expected to reach 38.42 USD Billion by 2035, at a CAGR of 7.01% during the forecast period
• North America accounted for the largest market in 2024
• Hospitals dominated the market based on End-user in 2024
• Novartis, Regeneron Pharmaceuticals, Pfizer, Gilead Sciences, Celgene, Merck & Co., Amgen, AstraZeneca, Eli Lilly, Teva Pharmaceuticals, Sanofi, Johnson & Johnson, Roche, Bristol-Myers Squibb, and AbbVie are the key market players